1932

Abstract

Neural tube defects (NTDs) are the most severe congenital malformations of the central nervous system. The etiology is complex, with both genetic and environmental factors having important contributions. Researchers have known for the past two decades that maternal periconceptional use of the B vitamin folic acid can prevent many NTDs. Though this finding is arguably one of the most important recent discoveries in birth defect research, the mechanism by which folic acid exerts this benefit remains unknown. Research to date has focused on the hypothesis that an underlying genetic susceptibility interacts with folate-sensitive metabolic processes at the time of neural tube closure. Little progress has been made searching for risk-causative variants in candidate genes; therefore, more complex genetic and epigenetic methodologies are now being considered. This article reviews the research to date that has been targeted on this important gene-nutrient locus.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-nutr-071714-034235
2017-08-21
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/nutr/37/1/annurev-nutr-071714-034235.html?itemId=/content/journals/10.1146/annurev-nutr-071714-034235&mimeType=html&fmt=ahah

Literature Cited

  1. Afman LA, Van Der Put NM, Thomas CM, Trijbels JM, Blom HJ. 1.  2001. Reduced vitamin B12 binding by transcobalamin II increases the risk of neural tube defects. Q. J. Med. 94:159–66 [Google Scholar]
  2. Amorim MR, Lima MA, Castilla EE, Orioli IM. 2.  2007. Non-Latin European descent could be a requirement for association of NTDs and MTHFR variant 677C >T: a meta-analysis. Am. J. Med. Genet 143A1726–32 [Google Scholar]
  3. Anderson DD, Woeller CF, Stover PJ. 3.  2007. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase. Clin. Chem. Lab. Med. 45:1760–63 [Google Scholar]
  4. Aneji CN, Northrup H, Au KS. 4.  2012. Deep sequencing study of the MTHFR gene to identify variants associated with myelomeningocele. Birth Defects Res. A Clin. Mol. Teratol. 94:84–90 [Google Scholar]
  5. Atta CA, Fiest KM, Frolkis AD, Jette N, Pringsheim T. 5.  et al. 2016. Global birth prevalence of spina bifida by folic acid fortification status: a systematic review and meta-analysis. Am. J. Public Health 106:e24–34 [Google Scholar]
  6. Au KS, Ashley-Koch A, Northrup H. 6.  2010. Epidemiologic and genetic aspects of spina bifida and other neural tube defects. Dev. Disabil. Res. Rev. 16:6–15 [Google Scholar]
  7. Bailey SW, Ayling JE. 7.  2009. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. PNAS 106:15424–29 [Google Scholar]
  8. Barbera JP, Rodriguez TA, Greene ND, Weninger WJ, Simeone A. 8.  et al. 2002. Folic acid prevents exencephaly in Cited2 deficient mice. Hum. Mol. Genet. 11:283–93 [Google Scholar]
  9. Barrett JC, Fry B, Maller J, Daly MJ. 9.  2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinform 21:263–65 [Google Scholar]
  10. Bassuk AG, Muthuswamy LB, Boland R, Smith TL, Hulstrand AM. 10.  et al. 2013. Copy number variation analysis implicates the cell polarity gene glypican 5 as a human spina bifida candidate gene. Hum. Mol. Genet. 22:1097–111 [Google Scholar]
  11. Beaudin AE, Abarinov EV, Noden DM, Perry CA, Chu S. 11.  et al. 2011. Shmt1 and de novo thymidylate biosynthesis underlie folate-responsive neural tube defects in mice. Am. J. Clin. Nutr. 93:789–98 [Google Scholar]
  12. Benjamini Y, Hochberg Y. 12.  1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57:281–300 [Google Scholar]
  13. Berry RJ, Li Z, Erickson JD, Li S, Moore CA. 13.  et al. 1999. Prevention of neural-tube defects with folic acid in China. N. Engl. J. Med. 341:1485–90 [Google Scholar]
  14. Besser LM, Williams LJ, Cragan JD. 14.  2007. Interpreting changes in the epidemiology of anencephaly and spina bifida following folic acid fortification of the U.S. grain supply in the setting of long-term trends, Atlanta, Georgia, 1968–2003. Birth Defects Res. A Clin. Mol. Teratol. 79:730–36 [Google Scholar]
  15. Bhide P, Sagoo GS, Moorthie S, Burton H, Kar A. 15.  2013. Systematic review of birth prevalence of neural tube defects in India. Birth Defects Res. A Clin. Mol. Teratol. 97:437–43 [Google Scholar]
  16. Blom HJ, Shaw GM, den Heijer M, Finnell RH. 16.  2006. Neural tube defects and folate: case far from closed. Nat. Rev. Neurosci. 7:724–31 [Google Scholar]
  17. Botto LD, Moore CA, Khoury MJ, Erickson JD. 17.  1999. Neural-tube defects. N. Engl. J. Med. 341:1509–19 [Google Scholar]
  18. Botto LD, Yang Q. 18.  2000. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 151:862–77 [Google Scholar]
  19. Brody LC, Baker PJ, Chines PS, Musick A, Molloy AM. 19.  et al. 1999. Methionine synthase: high-resolution mapping of the human gene and evaluation as a candidate locus for neural tube defects. Mol. Genet. Metab. 67:324–33 [Google Scholar]
  20. Brody LC, Conley M, Cox C, Kirke PN, McKeever MP. 20.  et al. 2002. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am. J. Hum. Genet. 71:1207–15 [Google Scholar]
  21. Brosnan ME, MacMillan L, Stevens JR, Brosnan JT. 21.  2015. Division of labour: How does folate metabolism partition between one-carbon metabolism and amino acid oxidation?. Biochem. J. 472:135–46 [Google Scholar]
  22. Burgoon JM, Selhub J, Nadeau M, Sadler TW. 22.  2002. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 65:219–27 [Google Scholar]
  23. Carter M, Ulrich S, Oofuji Y, Williams DA, Ross ME. 23.  1999. Crooked tail (Cd) models human folate-responsive neural tube defects. Hum. Mol. Genet. 8:2199–204 [Google Scholar]
  24. Carter TC, Pangilinan F, Troendle JF, Molloy AM, VanderMeer J. 24.  et al. 2011. Evaluation of 64 candidate single nucleotide polymorphisms as risk factors for neural tube defects in a large Irish study population. Am. J. Med. Genet 155A14–21 [Google Scholar]
  25. Champion KM, Cook RJ, Tollaksen SL, Giometti CS. 25.  1994. Identification of a heritable deficiency of the folate-dependent enzyme 10-formyltetrahydrofolate dehydrogenase in mice. PNAS 91:11338–42 [Google Scholar]
  26. Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S. 26.  et al. 2001. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10:433–43 [Google Scholar]
  27. Connealy BD, Northrup H, Au KS. 27.  2014. Genetic variations in the GLUT3 gene associated with myelomeningocele. Am. J. Obstet. Gynecol. 211:305.e1–e8 [Google Scholar]
  28. Copp AJ, Greene ND. 28.  2010. Genetics and development of neural tube defects. J. Pathol. 220:217–30 [Google Scholar]
  29. Copp AJ, Greene ND. 29.  2013. Neural tube defects: disorders of neurulation and related embryonic processes. Wiley Interdiscip. Rev. Dev. Biol. 2:213–27 [Google Scholar]
  30. Czeizel AE, Dudas I. 30.  1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327:1832–35 [Google Scholar]
  31. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. 31.  1995. Folate levels and neural tube defects. Implications for prevention. JAMA 274:1698–702 [Google Scholar]
  32. De Marco P, Merello E, Calevo MG, Mascelli S, Raso A. 32.  et al. 2006. Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G>A polymorphism for neural tube defect risk. J. Hum. Genet. 51:98–103 [Google Scholar]
  33. Deak KL, Siegel DG, George TM, Gregory S, Ashley-Koch A, Speer MC. 33.  2008. Further evidence for a maternal genetic effect and a sex-influenced effect contributing to risk for human neural tube defects. Birth Defects Res. A Clin. Mol. Teratol. 82:662–69 [Google Scholar]
  34. Di Pietro E, Sirois J, Tremblay ML, MacKenzie RE. 34.  2002. Mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase is essential for embryonic development. Mol. Cell Biol. 22:4158–66 [Google Scholar]
  35. Drainer E, May HM, Tolmie JL. 35.  1991. Do familial neural tube defects breed true?. J. Med. Genet 28605–8 [Google Scholar]
  36. Economides DL, Ferguson J, Mackenzie IZ, Darley J, Ware II, Holmes-Siedle M. 36.  1992. Folate and vitamin B12 concentrations in maternal and fetal blood, and amniotic fluid in second trimester pregnancies complicated by neural tube defects. Br. J. Obstet. Gynaecol. 99:23–25 [Google Scholar]
  37. Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T. 37.  et al. 2007. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol. Genet. Metab. 91:85–97 [Google Scholar]
  38. Elwood JM, Elwood JH. 38.  1980. Epidemiology of Anencephalus and Spina Bifida New York: Oxford Univ. Press
  39. Elwood JM, Little J, Elwood JH. 39.  1992. Epidemiology and Control of Neural Tube Defects Oxford: Oxford Univ. Press
  40. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. 40.  1995. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56:142–50 [Google Scholar]
  41. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. 41.  2014. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:298–302 [Google Scholar]
  42. Field MS, Kamynina E, Agunloye OC, Liebenthal RP, Lamarre SG. 42.  et al. 2014. Nuclear enrichment of folate cofactors and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) protect de novo thymidylate biosynthesis during folate deficiency. J. Biol. Chem. 289:29642–50 [Google Scholar]
  43. Fisk Green R, Byrne J, Crider KS, Gallagher M, Koontz D, Berry RJ. 43.  2013. Folate-related gene variants in Irish families affected by neural tube defects. Front. Genet. 4:223 [Google Scholar]
  44. Franke B, Vermeulen SH, Steegers-Theunissen RP, Coenen MJ, Schijvenaars MM. 44.  et al. 2009. An association study of 45 folate-related genes in spina bifida: involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1). Birth Defects Res. A Clin. Mol. Teratol. 85:216–26 [Google Scholar]
  45. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG. 45.  et al. 2002. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. PNAS 99:5606–11 [Google Scholar]
  46. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA. 46.  et al. 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:111–13 [Google Scholar]
  47. Gao L, Chalupsky K, Stefani E, Cai H. 47.  2009. Mechanistic insights into folic acid-dependent vascular protection: dihydrofolate reductase-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J. Mol. Cell Cardiol. 47:752–60 [Google Scholar]
  48. Garabedian BH, Fraser FC. 48.  1993. Upper and lower neural tube defects: an alternate hypothesis. J. Med. Genet 30849–51 [Google Scholar]
  49. Gardiki-Kouidou P, Seller MJ. 49.  1988. Amniotic fluid folate, vitamin B12 and transcobalamins in neural tube defects. Clin. Genet. 33:441–48 [Google Scholar]
  50. Gelineau-van Waes J, Heller S, Bauer LK, Wilberding J, Maddox JR. 50.  et al. 2008. Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Res. A Clin. Mol. Teratol. 82:494–507 [Google Scholar]
  51. 51. Genomes Proj. Consort. 2015. A global reference for human genetic variation. Nature 526:68–74 [Google Scholar]
  52. Gorroochurn P, Hodge SE, Heiman GA, Durner M, Greenberg DA. 52.  2007. Non-replication of association studies: “pseudo-failures” to replicate?. Genet. Med. 9:325–31 [Google Scholar]
  53. Greene ND, Copp AJ. 53.  2014. Neural tube defects. Annu. Rev. Neurosci. 37:221–42 [Google Scholar]
  54. Greene ND, Stanier P, Copp AJ. 54.  2009. Genetics of human neural tube defects. Hum. Mol. Genet. 18:R113–29 [Google Scholar]
  55. Harris MJ, Juriloff DM. 55.  2007. Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res. A Clin. Mol. Teratol. 79:187–210 [Google Scholar]
  56. Harris MJ, Juriloff DM. 56.  2010. An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. Birth Defects Res. A Clin. Mol. Teratol. 88:653–69 [Google Scholar]
  57. Heid MK, Bills ND, Hinrichs SH, Clifford AJ. 57.  1992. Folate deficiency alone does not produce neural tube defects in mice. J. Nutr. 122:888–94 [Google Scholar]
  58. Herbig K, Chiang EP, Lee LR, Hills J, Shane B, Stover PJ. 58.  2002. Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J. Biol. Chem. 277:38381–89 [Google Scholar]
  59. Jakubowski H, Perla-Kajan J, Finnell RH, Cabrera RM, Wang H. 59.  et al. 2009. Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice. FASEB J 23:1721–27 [Google Scholar]
  60. Jarrett JT, Hoover DM, Ludwig ML, Matthews RG. 60.  1998. The mechanism of adenosylmethionine-dependent activation of methionine synthase: a rapid kinetic analysis of intermediates in reductive methylation of Cob(II)alamin enzyme. Biochemistry 37:12649–58 [Google Scholar]
  61. Jiang J, Zhang Y, Wei L, Sun Z, Liu Z. 61.  2014. Association between MTHFD1 G1958A polymorphism and neural tube defects susceptibility: a meta-analysis. PLOS ONE 9:e101169 [Google Scholar]
  62. Joo JG, Beke A, Papp Z, Csaba A, Rab A, Papp C. 62.  2007. Risk of recurrence in major central nervous system malformations between 1976 and 2005. Prenat. Diagn. 27:1028–32 [Google Scholar]
  63. Källén B, Löfkvist E. 63.  1984. Time trends of spina bifida in Sweden 1947–81. J. Epidemiol. Community Health 38:103–7 [Google Scholar]
  64. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. 64.  1991. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 48:536–45 [Google Scholar]
  65. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. 65.  1988. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43:414–21 [Google Scholar]
  66. Khoshnood B, Loane M, de Walle H, Arriola L, Addor MC. 66.  et al. 2015. Long term trends in prevalence of neural tube defects in Europe: population based study. BMJ 351:h5949 [Google Scholar]
  67. Kirke PN, Daly LE, Elwood JH. 67.  1992. A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. Arch. Dis. Child 67:1442–46 [Google Scholar]
  68. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. 68.  1993. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q. J. Med. 86:703–8 [Google Scholar]
  69. Krupp DR, Soldano KL, Garrett ME, Cope H, Ashley-Koch AE, Gregory SG. 69.  2014. Missing genetic risk in neural tube defects: Can exome sequencing yield an insight?. Birth Defects Res. A Clin. Mol. Teratol. 100:642–46 [Google Scholar]
  70. Lamarre SG, Molloy AM, Reinke SN, Sykes BD, Brosnan ME, Brosnan JT. 70.  2012. Formate can differentiate between hyperhomocysteinemia due to impaired remethylation and impaired transsulfuration. Am. J. Physiol. Endocrinol. Metab. 302:E61–67 [Google Scholar]
  71. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. 71.  1981. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ 282:1509–11 [Google Scholar]
  72. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E. 72.  et al. 2016. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–91 [Google Scholar]
  73. Lemay P, Guyot MC, Tremblay E, Dionne-Laporte A, Spiegelman D. 73.  et al. 2015. Loss-of-function de novo mutations play an important role in severe human neural tube defects. J. Med. Genet 52493–97 [Google Scholar]
  74. Lencz T, Malhotra AK. 74.  2015. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol. Psychiatry 20:820–26 [Google Scholar]
  75. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R. 75.  2005. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am. J. Clin. Nutr. 82:188–95 [Google Scholar]
  76. Lin W, Zhang Z, Srajer G, Chen YC, Huang M. 76.  et al. 2008. Proper expression of the Gcn5 histone acetyltransferase is required for neural tube closure in mouse embryos. Dev. Dyn. 237:928–40 [Google Scholar]
  77. Liu J, Qi J, Yu X, Zhu J, Zhang L. 77.  et al. 2014. Investigations of single nucleotide polymorphisms in folate pathway genes in Chinese families with neural tube defects. J. Neurol. Sci. 337:61–66 [Google Scholar]
  78. Liu J, Zhang Y, Jin L, Li G, Wang L. 78.  et al. 2015. Variants in maternal COMT and MTHFR genes and risk of neural tube defects in offspring. Metab. Brain Dis. 30:507–13 [Google Scholar]
  79. Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O. 79.  et al. 2005. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 65:887–97 [Google Scholar]
  80. MacFarlane AJ, Liu X, Perry CA, Flodby P, Allen RH. 80.  et al. 2008. Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetrahydrofolate but is not essential in mice. J. Biol. Chem. 283:25846–53 [Google Scholar]
  81. Martinez CA, Northrup H, Lin JI, Morrison AC, Fletcher JM. 81.  et al. 2009. Genetic association study of putative functional single nucleotide polymorphisms of genes in folate metabolism and spina bifida. Am. J. Obstet. Gynecol. 201:394.e1–11 [Google Scholar]
  82. Martiniova L, Field MS, Finkelstein JL, Perry CA, Stover PJ. 82.  2015. Maternal dietary uridine causes, and deoxyuridine prevents, neural tube closure defects in a mouse model of folate-responsive neural tube defects. Am. J. Clin. Nutr. 101:860–69 [Google Scholar]
  83. Meng J, Han L, Zhuang B. 83.  2015. Association between MTHFD1 polymorphisms and neural tube defect susceptibility. J. Neurol. Sci. 348:188–94 [Google Scholar]
  84. Mills JL, Tuomilehto J, Yu KF, Colman N, Blaner WS. 84.  et al. 1992. Maternal vitamin levels during pregnancies producing infants with neural tube defects. J. Pediatr. 120:863–71 [Google Scholar]
  85. Molloy AM, Brody LC, Mills JL, Scott JM, Kirke PN. 85.  2009. The search for genetic polymorphisms in the homocysteine/folate pathway that contribute to the etiology of human neural tube defects. Birth Defects Res. A Clin. Mol. Teratol. 85:285–94 [Google Scholar]
  86. Molloy AM, Kirke P, Hillary I, Weir DG, Scott JM. 86.  1985. Maternal serum folate and vitamin B12 concentrations in pregnancies associated with neural tube defects. Arch. Dis. Child. 60:660–65 [Google Scholar]
  87. Molloy AM, Kirke PN, Troendle JF, Burke H, Sutton M. 87.  et al. 2009. Maternal vitamin B12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic acid fortification. Pediatrics 123:917–23 [Google Scholar]
  88. Momb J, Appling DR. 88.  2014. Mitochondrial one-carbon metabolism and neural tube defects. Birth Defects Res. A Clin. Mol. Teratol. 100:576–83 [Google Scholar]
  89. Momb J, Lewandowski JP, Bryant JD, Fitch R, Surman DR. 89.  et al. 2013. Deletion of Mthfd1l causes embryonic lethality and neural tube and craniofacial defects in mice. PNAS 110:549–54 [Google Scholar]
  90. Moore CA, Li S, Li Z, Hong SX, Gu HQ. 90.  et al. 1997. Elevated rates of severe neural tube defects in a high-prevalence area in Northern China. Am. J. Med. Genet 73113–18 [Google Scholar]
  91. 91. MRC Vitam. Study Res. Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338:131–37 [Google Scholar]
  92. Murphy M, Seagroatt V, Hey K, O'Donnell M, Godden M. 92.  et al. 1996. Neural tube defects 1974–94: down but not out. Arch. Dis. Child. 75:F133–34 [Google Scholar]
  93. Narisawa A, Komatsuzaki S, Kikuchi A, Niihori T, Aoki Y. 93.  et al. 2012. Mutations in genes encoding the glycine cleavage system predispose to neural tube defects in mice and humans. Hum. Mol. Genet. 21:1496–503 [Google Scholar]
  94. O'Leary VB, Mills JL, Parle-McDermott A, Pangilinan F, Molloy AM. 94.  et al. 2005. Screening for new MTHFR polymorphisms and NTD risk. Am. J. Med. Genet 138A99–106 [Google Scholar]
  95. O'Rahilly R, Muller F. 95.  1994. Neurulation in the normal human embryo. Ciba Found. Symp. 181:70–82 [Google Scholar]
  96. O'Rahilly R, Muller F. 96.  2002. The two sites of fusion of the neural folds and the two neuropores in the human embryo. Teratology 65:162–70 [Google Scholar]
  97. Ouyang S, Li Y, Liu Z, Chang H, Wu J. 97.  2013. Association between MTR A2756G and MTRR A66G polymorphisms and maternal risk for neural tube defects: a meta-analysis. Gene 515:308–12 [Google Scholar]
  98. Ouyang S, Liu Z, Li Y, Ma F, Wu J. 98.  2014. Cystathionine beta-synthase 844ins68 polymorphism is unrelated to susceptibility to neural tube defects. Gene 535:119–23 [Google Scholar]
  99. Ouyang S, Liu Z, Li Y, Wu J. 99.  2013. Meta-analyses on the association of MTR A2756G and MTRR A66G polymorphisms with neural tube defect risks in Caucasian children. J. Matern.-Fetal Neonatal Med. 26:1166–70 [Google Scholar]
  100. Pangilinan F, Mitchell A, VanderMeer J, Molloy AM, Troendle J. 100.  et al. 2010. Transcobalamin II receptor polymorphisms are associated with increased risk for neural tube defects. J. Med. Genet 47677–85 [Google Scholar]
  101. Pangilinan F, Molloy AM, Mills JL, Troendle JF, Parle-McDermott A. 101.  et al. 2012. Evaluation of common genetic variants in 82 candidate genes as risk factors for neural tube defects. BMC Med. Genet 1362 [Google Scholar]
  102. Parle-McDermott A, Kirke PN, Mills JL, Molloy AM, Cox C. 102.  et al. 2006. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur. J. Hum. Genet. 14:768–72 [Google Scholar]
  103. Piao W, Guo J, Bao Y, Wang F, Zhang T. 103.  et al. 2016. Analysis of polymorphisms of genes associated with folate-mediated one-carbon metabolism and neural tube defects in Chinese Han population. Birth Defects Res. A Clin. Mol. Teratol. 106:232–39 [Google Scholar]
  104. Piedrahita JA, Oetama B, Bennett GD, van Waes J, Kamen BA. 104.  et al. 1999. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat. Genet. 23:228–32 [Google Scholar]
  105. Pike ST, Rajendra R, Artzt K, Appling DR. 105.  2010. Mitochondrial C1-tetrahydrofolate synthase (MTHFD1L) supports the flow of mitochondrial one-carbon units into the methyl cycle in embryos. J. Biol. Chem. 285:4612–20 [Google Scholar]
  106. Prasad RB, Groop L. 106.  2015. Genetics of type 2 diabetes: pitfalls and possibilities. Genes 6:87–123 [Google Scholar]
  107. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA. 107.  et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559–75 [Google Scholar]
  108. Ray JG, Wyatt PR, Thompson MD, Vermeulen MJ, Meier C. 108.  et al. 2007. Vitamin B12 and the risk of neural tube defects in a folic-acid-fortified population. Epidemiology 18:362–66 [Google Scholar]
  109. Rochtus A, Izzi B, Vangeel E, Louwette S, Wittevrongel C. 109.  et al. 2015. DNA methylation analysis of Homeobox genes implicates HOXB7 hypomethylation as risk factor for neural tube defects. Epigenetics 10:92–101 [Google Scholar]
  110. Rochtus A, Winand R, Laenen G, Vangeel E, Izzi B. 110.  et al. 2016. Methylome analysis for spina bifida shows SOX18 hypomethylation as a risk factor with evidence for a complex (epi)genetic interplay to affect neural tube development. Clin. Epigenet. 8:108 [Google Scholar]
  111. Ruggiero JE, Northrup H, Au KS. 111.  2015. Association of facilitated glucose transporter 2 gene variants with the myelomeningocele phenotype. Birth Defects Res. A Clin. Mol. Teratol. 103:479–87 [Google Scholar]
  112. Sadewa AH, Sutomo R, Istiadjid M, Nishiyama K, Shirakawa T. 112.  et al. 2004. C677T mutation in the MTHFR gene was not found in patients with frontoethmoidal encephalocele in East Java, Indonesia. Pediatr. Int. 46:409–14 [Google Scholar]
  113. Schorah CJ, Smithells RW, Scott J. 113.  1980. Vitamin B12 and anencephaly. Lancet 1:880 [Google Scholar]
  114. Shah RH, Northrup H, Hixson JE, Morrison AC, Au KS. 114.  2016. Genetic association of the glycine cleavage system genes and myelomeningocele. Birth Defects Res. A Clin. Mol. Teratol. 106:847–53 [Google Scholar]
  115. Shaw GM, Lu W, Zhu H, Yang W, Briggs FB. 115.  et al. 2009. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med. Genet 1049 [Google Scholar]
  116. Smith ZD, Meissner A. 116.  2013. DNA methylation: roles in mammalian development. Nat. Rev. Genet. 14:204–20 [Google Scholar]
  117. Smithells RW, Sheppard S. 117.  1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1:647 [Google Scholar]
  118. Smithells RW, Sheppard S, Schorah CJ. 118.  1976. Vitamin deficiencies and neural tube defects. Arch. Dis. Child. 51:944–50 [Google Scholar]
  119. Smithells RW, Sheppard S, Wild J, Schorah CJ. 119.  1989. Prevention of neural tube defect recurrences in Yorkshire: final report. Lancet 2:498–99 [Google Scholar]
  120. Spiegelstein O, Mitchell LE, Merriweather MY, Wicker NJ, Zhang Q. 120.  et al. 2004. Embryonic development of folate binding protein-1 (Folbp1) knockout mice: effects of the chemical form, dose, and timing of maternal folate supplementation. Dev. Dyn. 231:221–31 [Google Scholar]
  121. Spielman RS, McGinnis RE, Ewens WJ. 121.  1993. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 52:506–16 [Google Scholar]
  122. Stern LL, Mason JB, Selhub J, Choi SW. 122.  2000. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol. Biomark. Prev. 9:849–53 [Google Scholar]
  123. Stover PJ, Field MS. 123.  2011. Trafficking of intracellular folates. Adv. Nutr. 2:325–31 [Google Scholar]
  124. Suarez L, Hendricks K, Felkner M, Gunter E. 124.  2003. Maternal serum B12 levels and risk for neural tube defects in a Texas-Mexico border population. Ann. Epidemiol. 13:81–88 [Google Scholar]
  125. Sudiwala S, De Castro SC, Leung KY, Brosnan JT, Brosnan ME. 125.  et al. 2016. Formate supplementation enhances folate-dependent nucleotide biosynthesis and prevents spina bifida in a mouse model of folic acid-resistant neural tube defects. Biochimie 126:63–70 [Google Scholar]
  126. Susser M, Stein Z. 126.  1994. Timing in prenatal nutrition: a reprise of the Dutch Famine Study. Nutr. Rev. 52:84–94 [Google Scholar]
  127. Swanson DA, Liu ML, Baker PJ, Garrett L, Stitzel M. 127.  et al. 2001. Targeted disruption of the methionine synthase gene in mice. Mol. Cell Biol. 21:1058–65 [Google Scholar]
  128. Tibbetts AS, Appling DR. 128.  2010. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 30:57–81 [Google Scholar]
  129. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK. 129.  et al. 1995. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070–71 [Google Scholar]
  130. Wald NJ, Hackshaw AD, Stone R, Sourial NA. 130.  1996. Blood folic acid and vitamin B12 in relation to neural tube defects. Br. J. Obstet. Gynaecol. 103:319–24 [Google Scholar]
  131. Wang F, Wang J, Guo J, Chen X, Guan Z. 131.  et al. 2013. PCMT1 gene polymorphisms, maternal folate metabolism, and neural tube defects: a case-control study in a population with relatively low folate intake. Genes Nutr 8:581–87 [Google Scholar]
  132. Wang L, Shangguan S, Chang S, Yu X, Wang Z. 132.  et al. 2016. Determining the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and genomic DNA methylation level: a meta-analysis. Birth Defects Res. A Clin. Mol. Teratol. 106:667–74 [Google Scholar]
  133. Wang Y, Liu Y, Ji W, Qin H, Wu H. 133.  et al. 2015. Analysis of MTR and MTRR polymorphisms for neural tube defects risk association. Medicine 94:e1367 [Google Scholar]
  134. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R. 134.  et al. 1995. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. PNAS 92:1585–89 [Google Scholar]
  135. Welter D, MacArthur J, Morales J, Burdett T, Hall P. 135.  et al. 2014. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42:D1001–6 [Google Scholar]
  136. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H. 136.  et al. 1995. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. Q. J. Med. 88:763–66 [Google Scholar]
  137. Wilde JJ, Petersen JR, Niswander L. 137.  2014. Genetic, epigenetic, and environmental contributions to neural tube closure. Annu. Rev. Genet. 48:583–611 [Google Scholar]
  138. Witte JS, Visscher PM, Wray NR. 138.  2014. The contribution of genetic variants to disease depends on the ruler. Nat. Rev. Genet. 15:765–76 [Google Scholar]
  139. Wlodarczyk BJ, Tang LS, Triplett A, Aleman F, Finnell RH. 139.  2006. Spontaneous neural tube defects in splotch mice supplemented with selected micronutrients. Toxicol. Appl. Pharmacol. 213:55–63 [Google Scholar]
  140. Wright AJ, Finglas PM, Dainty JR, Wolfe CA, Hart DJ. 140.  et al. 2005. Differential kinetic behavior and distribution for pteroylglutamic acid and reduced folates: a revised hypothesis of the primary site of PteGlu metabolism in humans. J. Nutr. 135:619–23 [Google Scholar]
  141. Wu J, Bao Y, Lu X, Wu L, Zhang T. 141.  et al. 2015. Polymorphisms in MTHFD1 gene and susceptibility to neural tube defects: a case-control study in a Chinese Han population with relatively low folate levels. Med. Sci. Monit 212630–37 [Google Scholar]
  142. Wu L, Lu X, Guo J, Zhang T, Wang F, Bao Y. 142.  2016. Association between ALDH1L1 gene polymorphism and neural tube defects in the Chinese Han population. Neurol. Sci. 37:1049–54 [Google Scholar]
  143. Yadav U, Kumar P, Yadav SK, Mishra OP, Rai V. 143.  2015. Polymorphisms in folate metabolism genes as maternal risk factor for neural tube defects: an updated meta-analysis. Metab. Brain Dis. 30:7–24 [Google Scholar]
  144. Yan L, Zhao L, Long Y, Zou P, Ji G. 144.  et al. 2012. Association of the maternal MTHFR C677T polymorphism with susceptibility to neural tube defects in offspring: evidence from 25 case-control studies. PLOS ONE 7:e41689 [Google Scholar]
  145. Yang M, Yang L, Qi L, Guo Y, Lin X. 145.  et al. 2013. Association between the methionine synthase A2756G polymorphism and neural tube defect risk: a meta-analysis. Gene 520:7–13 [Google Scholar]
  146. Yang Y, Chen J, Wang B, Ding C, Liu H. 146.  2015. Association between MTHFR C677T polymorphism and neural tube defect risks: a comprehensive evaluation in three groups of NTD patients, mothers, and fathers. Birth Defects Res. A Clin. Mol. Teratol. 103:488–500 [Google Scholar]
  147. Yates JR, Ferguson-Smith MA, Shenkin A, Guzman-Rodriguez R, White M, Clark BJ. 147.  1987. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects?. Clin. Genet. 31:279–87 [Google Scholar]
  148. Yu Y, Wang F, Bao Y, Lu X, Quan L, Lu P. 148.  2014. Association between MTHFR gene polymorphism and NTDs in Chinese Han population. Int. J. Clin. Exp. Med. 7:2901–6 [Google Scholar]
  149. Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H. 149.  et al. 2016. Describing the prevalence of neural tube defects worldwide: a systematic literature review. PLOS ONE 11:e0151586 [Google Scholar]
  150. Zhang T, Lou J, Zhong R, Wu J, Zou L. 150.  et al. 2013. Genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLOS ONE 8:e59570 [Google Scholar]
  151. Zhang T, Xin R, Gu X, Wang F, Pei L. 151.  et al. 2009. Maternal serum vitamin B12, folate and homocysteine and the risk of neural tube defects in the offspring in a high-risk area of China. Public Health Nutr 12:680–86 [Google Scholar]
  152. Zhao Q, Behringer RR, de Crombrugghe B. 152.  1996. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat. Genet. 13:275–83 [Google Scholar]
  153. Zollner S, Pritchard JK. 153.  2007. Overcoming the winner's curse: estimating penetrance parameters from case-control data. Am. J. Hum. Genet. 80:605–15 [Google Scholar]
/content/journals/10.1146/annurev-nutr-071714-034235
Loading
/content/journals/10.1146/annurev-nutr-071714-034235
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error